Healthcare provider profile · identity verified

Spencer Tingey, D.O.

Allopathic & Osteopathic Physicians|Family Medicine · TAYLORSVILLE, UT · NPI 1962829374

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Spencer Tingey, D.O. received $249.67 in general payments during 2025 across 8 reported records.

Boston Scientific Corporation accounted for 60.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$249.67

8 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Boston Scientific Corporation Unresolved — no canonical attribution shown $150.2560.2%62025
COLOPLAST CORP Unresolved — no canonical attribution shown $99.4239.8%22025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$249.678

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
AMS 800 Artificial Urinary Sphincter
Normalized: ams 800 artificial urinary sphincter
Device Boston Scientific Corporation $75.95 2 2025
Source payment records
Altis
Normalized: altis
Device COLOPLAST CORP $75.57 1 2025
Source payment records
AMS 700
Normalized: ams 700
Device Boston Scientific Corporation $74.30 4 2025
Source payment records
Titan
Normalized: titan
Device COLOPLAST CORP $23.85 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium21368
OmeprazoleOmeprazole11832
Levothyroxine SodiumLevothyroxine Sodium10329
Losartan PotassiumLosartan Potassium10037
Amlodipine BesylateAmlodipine Besylate9530
GabapentinGabapentin8922
LisinoprilLisinopril8927
Trazodone HclTrazodone Hcl8625
ClonazepamClonazepam81suppressed
Metformin HclMetformin Hcl7225
Tamsulosin HclTamsulosin Hcl7119
Tizanidine HclTizanidine Hcl6821
Pantoprazole SodiumPantoprazole Sodium5617
PregabalinPregabalin56suppressed
CelecoxibCelecoxib5421
AlprazolamAlprazolam53suppressed
CarvedilolCarvedilol5312
Tramadol HclTramadol Hcl48suppressed
Ondansetron OdtOndansetron4411
FurosemideFurosemide3912
Metoprolol SuccinateMetoprolol Succinate3913
ClopidogrelClopidogrel Bisulfate37suppressed
Albuterol Sulfate HfaAlbuterol Sulfate3314
Zolpidem TartrateZolpidem Tartrate33suppressed
Rosuvastatin CalciumRosuvastatin Calcium32suppressed
Diclofenac SodiumDiclofenac Sodium3114
Fluticasone PropionateFluticasone Propionate3111
HydrochlorothiazideHydrochlorothiazide30suppressed
MeloxicamMeloxicam30suppressed
PrednisonePrednisone3022
FamotidineFamotidine29suppressed
Fluoxetine HclFluoxetine Hcl29suppressed
IbuprofenIbuprofen2812
Propranolol HclPropranolol Hcl28suppressed
Escitalopram OxalateEscitalopram Oxalate26suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26suppressed
TrulicityDulaglutide26suppressed
OzempicSemaglutide23suppressed
SymbicortBudesonide/Formoterol Fumarate23suppressed
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22suppressed
SimvastatinSimvastatin21suppressed
MirtazapineMirtazapine19suppressed
AllopurinolAllopurinol18suppressed
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide18suppressed
Alendronate SodiumAlendronate Sodium17suppressed
Divalproex SodiumDivalproex Sodium17suppressed
FarxigaDapagliflozin Propanediol17suppressed
Amitriptyline HclAmitriptyline Hcl16suppressed
ColchicineColchicine16suppressed
JardianceEmpagliflozin16suppressed
Bupropion XlBupropion Hcl15suppressed
Duloxetine HclDuloxetine Hcl15suppressed
Hydroxyzine HclHydroxyzine Hcl15suppressed
Metformin Hcl ErMetformin Hcl15suppressed
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst1513
SucralfateSucralfate15suppressed
TopiramateTopiramate15suppressed
Triamcinolone AcetonideTriamcinolone Acetonide15suppressed
AzithromycinAzithromycin1414
DiazepamDiazepam14suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13suppressed
Metoprolol TartrateMetoprolol Tartrate13suppressed
Montelukast SodiumMontelukast Sodium13suppressed
ClozapineClozapine12suppressed
FenofibrateFenofibrate Nanocrystallized12suppressed
FinasterideFinasteride12suppressed
Paroxetine HclParoxetine Hcl12suppressed
Pioglitazone HclPioglitazone Hcl12suppressed
Pravastatin SodiumPravastatin Sodium12suppressed
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11suppressed
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11suppressed
IrbesartanIrbesartan11suppressed
LamotrigineLamotrigine11suppressed
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide11suppressed
PhenobarbitalPhenobarbital11suppressed
Testosterone CypionateTestosterone Cypionate11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $249.67 · 8 records Boston Scientific Corporation AMS 700, AMS 800 Artificial Urinary Sphincter, Altis, Titan
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error